Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nadifloxacin is a topical fluoroquinolone antibiotic primarily used for the treatment of acne vulgaris and various bacterial skin infections. It exhibits broad-spectrum antibacterial activity against aerobic Gram-positive, Gram-negative, and anaerobic bacteria—including methicillin-resistant Staphylococcus aureus (MRSA) and Cutibacterium acnes. Its mechanism of action involves inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription in bacteria. This dual inhibition disrupts bacterial DNA synthesis, leading to bactericidal effects[1][3][8]. Nadifloxacin also demonstrates anti-inflammatory properties by inhibiting proinflammatory cytokine production in immune cells and keratinocytes[6]. The drug is approved for use in Japan and several other countries as a topical agent for acne vulgaris and skin infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nadifloxacin.